Related Experiment Videos
Psoriasis and human immunodeficiency virus infection.
M L Obuch1, T A Maurer, B Becker
1Department of Dermatology, San Francisco General Hospital, California.
Journal of the American Academy of Dermatology
|November 1, 1992
Summary
Psoriasis in patients with human immunodeficiency virus (HIV) infection can be severe, but standard therapies are effective. The presence of psoriasis or its treatment does not appear to negatively impact survival rates in HIV-positive individuals.
Area of Science:
- Dermatology
- Infectious Diseases
- Immunology
Background:
- Psoriasis in human immunodeficiency virus (HIV) infected individuals is often severe and may impact survival.
- Understanding the interplay between psoriasis and HIV is crucial for patient management.
Purpose of the Study:
- To investigate the natural history of psoriasis in HIV-infected patients.
- To evaluate the efficacy of psoriasis treatments in this population.
- To determine the effect of psoriasis and its management on survival outcomes in HIV-infected individuals.
Main Methods:
- An observational cohort study was conducted over a 2-year period.
- Fifty individuals with both psoriasis and HIV infection were followed.
- Patients were categorized into two groups based on the onset of psoriasis relative to the HIV epidemic in San Francisco.
Main Results:
- Psoriasis onset before 1978 (Group I) was associated with earlier age of onset and family history. Psoriasis onset after 1978 (Group II) showed a higher prevalence of palmoplantar and inverse psoriasis.
- Severe psoriasis was observed in 25% of patients.
- Median survival after acquired immunodeficiency syndrome (AIDS) diagnosis was 19 months, comparable to the general AIDS population.
Conclusions:
- Psoriasis in HIV disease can range from mild to severe.
- Standard psoriasis therapies, including zidovudine, are effective for management.
- Psoriasis and its treatment do not appear to adversely affect survival in HIV-infected patients.